Bupropion Hydrochloride Patent Expiration
Bupropion Hydrochloride was first introduced by Glaxosmithkline
Bupropion Hydrochloride Patents
Given below is the list of patents protecting Bupropion Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Forfivo Xl | US7674479 | Sustained-release bupropion and bupropion/mecamylamine tablets | Aug 23, 2028 | Twi Pharms |
| Wellbutrin Xl | US6096341 | Delayed release tablet of bupropion hydrochloride |
Oct 30, 2018
(Expired) | Bausch |
| Wellbutrin Sr | US5358970 | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
Aug 12, 2013
(Expired) | Glaxosmithkline |
| Wellbutrin Sr | US5427798 | Controlled sustained release tablets containing bupropion |
Aug 12, 2013
(Expired) | Glaxosmithkline |
| Wellbutrin Sr | US5731000 | Stabilized pharmaceutical composition containing bupropion |
Aug 12, 2013
(Expired) | Glaxosmithkline |
| Wellbutrin Sr | US5763493 | Stabilized pharmaceutical |
Aug 12, 2013
(Expired) | Glaxosmithkline |
| Zyban | US5358970 | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
Aug 12, 2013
(Expired) | Glaxosmithkline |
| Zyban | US5427798 | Controlled sustained release tablets containing bupropion |
Aug 12, 2013
(Expired) | Glaxosmithkline |
| Zyban | US5731000 | Stabilized pharmaceutical composition containing bupropion |
Aug 12, 2013
(Expired) | Glaxosmithkline |
| Zyban | US5763493 | Stabilized pharmaceutical |
Aug 12, 2013
(Expired) | Glaxosmithkline |
Bupropion Hydrochloride's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Bupropion Hydrochloride:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer | NRG Oncology | NA |
COMPLETED
(Jun 1, 2026)
| PHASE2 |